Early Access and Global Collaborations
As Life'n, we take a significant step in the healthcare sector by collaborating with global pharmaceutical companies to provide early access to innovative medicines. Innovative drugs offer great hope, particularly for patients battling serious illnesses who do not benefit adequately from existing treatment options.
In this context, we effectively manage early access processes in Turkey and international pharmaceutical systems to ensure timely access to these medicines for patients.
Early Access to Medicines in Turkey
-
Patient Access: We manage early access programs to provide unlicensed medicines and new treatment options to patients in Turkey.
Priority Patient Groups: We develop early access programs, particularly for patients who do not benefit from current treatments.
Regulatory Compliance: We ensure full compliance with legal regulations set by local health authorities.
Collaboration with Healthcare Professionals: We work closely with doctors and healthcare institutions to ensure patients receive the most appropriate treatments.
Access Through International Pharmaceutical Systems
-
Global Collaborations: We collaborate with international pharmaceutical manufacturers to provide Turkish patients with access to innovative treatments worldwide.
Approved Treatments: We facilitate access to medicines that have been approved in developed countries but are not yet licensed in Turkey.
Clinical Data Monitoring: We assess clinical data of promising medicines to offer the best options for patients.
Global Partnerships and Effective Treatment Access
-
Innovative Treatment Options: Through our collaborations with global pharmaceutical companies, we accelerate access to the latest treatment options.
Clinical Research: We evaluate opportunities for patients to participate in clinical trials, reaching more patients in need.
Compliance with Health Authorities: We ensure that medications reach patients as quickly as possible by adhering to regulatory processes.
Patient-Centric Approach and Safety
-
Patient Safety is Our Priority: We maintain the highest standards of patient safety in early access programs.
Treatments Supported by Scientific Evidence: We deliver medicines that have been clinically validated for safety and efficacy.
Follow-up with Healthcare Professionals: We collaborate with doctors and specialists to continuously monitor patient health during treatment.
Collaborations with Global Pharmaceutical Companies
Strategic collaborations with global pharmaceutical companies play a crucial role in ensuring early access to innovative medicines.
Through these partnerships:
-
Faster Access for Patients: We provide rapid access to treatment options worldwide.
Contribution to Scientific Research: We support the effectiveness of innovative treatments through clinical research and scientific data.
Reliable Medicine Supply: We ensure that medicines undergo necessary testing and are delivered safely to patients.
At every stage, we prioritize patient safety and ensure that innovative medicines reach patients effectively and reliably.
As Life'n, we continue to manage treatment processes with the highest levels of transparency and trust.